Original data (with adjusted standard errors for multi-arm studies):

              treat1       treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
12       eszopiclone      placebo  0.9353 0.4839     0.4839     0.6221     2         
18  BZD-intermediate      placebo  0.7110 0.8900     0.8900     0.9721     2         
47           placebo     zolpidem -0.3781 0.4408     0.4408     0.5892     2         
51          BZD-long      placebo  0.4426 0.2478     0.2877     0.5587     3        *
51         BZD-short      placebo  0.0580 0.2829     0.3941     0.6096     3        *
51          BZD-long    BZD-short  0.3845 0.2473     0.2869     0.5581     3        *
52          BZD-long    zopiclone -0.6165 0.6473     0.6473     0.7562     2         
54  BZD-intermediate     BZD-long -0.5710 0.5890     0.5890     0.7070     2         
55          BZD-long    BZD-short  1.0311 0.6145     0.6145     0.7284     2         
56  BZD-intermediate    BZD-short -0.7426 0.5969     0.5969     0.7136     2         
60           doxepin      placebo  0.3340 0.1577     0.1577     0.4216     2         
61           doxepin      placebo  0.4519 0.1419     0.1419     0.4159     2         
70         melatonin      placebo  0.0639 0.3163     0.3163     0.5029     2         
71          BZD-long    BZD-short -0.2873 0.5803     0.5803     0.6997     2         
75           placebo    ramelteon -0.1359 0.0943     0.0943     0.4022     2         
77       eszopiclone      placebo  0.5924 0.1281     0.1281     0.4114     2         
79         BZD-short      placebo  0.3905 0.5032     0.6180     0.7818     3        *
79           placebo     zolpidem -0.3092 0.5020     0.6151     0.7795     3        *
79         BZD-short     zolpidem  0.0814 0.5001     0.6106     0.7759     3        *
80           placebo     zolpidem -1.2504 0.6313     0.6313     0.7425     2         
81           placebo     zolpidem -1.3268 0.6377     0.6377     0.7480     2         
83  BZD-intermediate      placebo  0.0917 0.3485     0.3485     0.5238     2         
85           placebo     zolpidem -0.0126 0.3339     0.3339     0.5141     2         
99      daridorexant     zolpidem  0.0812 0.1579     0.1819     0.5121     3        *
99           placebo     zolpidem -0.3574 0.1833     0.2597     0.5376     3        *
99      daridorexant      placebo  0.4386 0.1592     0.1840     0.5132     3        *
106      eszopiclone    zopiclone  0.1742 0.1421     0.1421     0.4160     2         
111 BZD-intermediate      placebo  0.3830 0.3353     0.4155     0.6339     3        *
111 BZD-intermediate trimipramine  0.0337 0.3289     0.3996     0.6237     3        *
111          placebo trimipramine -0.3493 0.3306     0.4036     0.6263     3        *
112          placebo     zolpidem -0.7360 0.2167     0.2167     0.4470     2         
114          placebo     zolpidem -0.4160 0.1434     0.1434     0.4165     2         
118 BZD-intermediate    BZD-short -0.3116 0.3585     0.3585     0.5304     2         
119          placebo     zolpidem -0.5824 0.3045     0.3045     0.4956     2         
122          placebo    zopiclone  0.0034 0.3934     0.3934     0.5546     2         
133        BZD-short     zaleplon  0.2527 0.2178     0.2530     0.5426     3        *
133          placebo     zaleplon  0.0731 0.2106     0.2407     0.5349     3        *
133        BZD-short      placebo  0.1797 0.2486     0.3540     0.5836     3        *
134          placebo     zaleplon -0.3188 0.2055     0.2055     0.4417     2         
137          placebo     zolpidem -0.2223 0.1423     0.1423     0.4161     2         
140        BZD-short     zolpidem  0.2031 0.2509     0.3083     0.5696     3        *
140          placebo     zolpidem -0.5518 0.2440     0.2923     0.5607     3        *
140        BZD-short      placebo  0.7549 0.2545     0.3179     0.5746     3        *
142 BZD-intermediate      placebo  1.8669 0.4110     0.4110     0.5673     2         
144      eszopiclone      placebo  0.4423 0.1266     0.1266     0.4110     2         
145          placebo    ramelteon -0.1181 0.1219     0.1219     0.4095     2         
153      lemborexant     zolpidem  0.4741 0.0777     0.0875     0.4861     3        *
153          placebo     zolpidem -0.2877 0.0951     0.1363     0.4953     3        *
153      lemborexant      placebo  0.7617 0.0850     0.0998     0.4897     3        *
154      lemborexant      placebo  4.5678 0.3450     0.3450     0.5214     2         
158          placebo  seltorexant -0.2521 0.1344     0.1506     0.5018     3        *
158          placebo     zolpidem -0.0103 0.1644     0.2561     0.5288     3        *
158      seltorexant     zolpidem  0.2419 0.1358     0.1526     0.5028     3        *
159     daridorexant      placebo  0.5799 0.0708     0.0708     0.3974     2         
160     daridorexant      placebo  0.3315 0.0811     0.0811     0.3993     2         

Number of treatment arms (by study):
    narms
12      2
18      2
47      2
51      3
52      2
54      2
55      2
56      2
60      2
61      2
70      2
71      2
75      2
77      2
79      3
80      2
81      2
83      2
85      2
99      3
106     2
111     3
112     2
114     2
118     2
119     2
122     2
133     3
134     2
137     2
140     3
142     2
144     2
145     2
153     3
154     2
158     3
159     2
160     2

Results (fixed effects model):

              treat1       treat2     SMD             95%-CI      Q leverage
12       eszopiclone      placebo  0.5293 [ 0.3606;  0.6980]   0.70     0.03
18  BZD-intermediate      placebo  0.4384 [ 0.1093;  0.7675]   0.09     0.04
47           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.00     0.01
51          BZD-long      placebo  0.6322 [ 0.2758;  0.9886]   0.43        .
51         BZD-short      placebo  0.4517 [ 0.2113;  0.6922]   1.00        .
51          BZD-long    BZD-short  0.1805 [-0.1703;  0.5312]   0.51        .
52          BZD-long    zopiclone  0.2803 [-0.1669;  0.7275]   1.92     0.12
54  BZD-intermediate     BZD-long -0.1938 [-0.6394;  0.2518]   0.41     0.15
55          BZD-long    BZD-short  0.1805 [-0.1703;  0.5312]   1.92     0.08
56  BZD-intermediate    BZD-short -0.0133 [-0.3725;  0.3458]   1.49     0.09
60           doxepin      placebo  0.3991 [ 0.1924;  0.6059]   0.17     0.45
61           doxepin      placebo  0.3991 [ 0.1924;  0.6059]   0.14     0.55
70         melatonin      placebo  0.0639 [-0.5560;  0.6839]   0.00     1.00
71          BZD-long    BZD-short  0.1805 [-0.1703;  0.5312]   0.65     0.10
75           placebo    ramelteon -0.1293 [-0.2754;  0.0169]   0.01     0.63
77       eszopiclone      placebo  0.5293 [ 0.3606;  0.6980]   0.24     0.45
79         BZD-short      placebo  0.4517 [ 0.2113;  0.6922]   0.01        .
79           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.01        .
79         BZD-short     zolpidem  0.0756 [-0.1777;  0.3289]   0.00        .
80           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   1.92     0.01
81           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   2.22     0.01
83  BZD-intermediate      placebo  0.4384 [ 0.1093;  0.7675]   0.99     0.23
85           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   1.19     0.02
99      daridorexant     zolpidem  0.0927 [-0.0427;  0.2280]   0.00        .
99           placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.01        .
99      daridorexant      placebo  0.4688 [ 0.3718;  0.5657]   0.03        .
106      eszopiclone    zopiclone  0.1774 [-0.0808;  0.4355]   0.00     0.86
111 BZD-intermediate      placebo  0.4384 [ 0.1093;  0.7675]   0.02        .
111 BZD-intermediate trimipramine  0.0611 [-0.5188;  0.6410]   0.00        .
111          placebo trimipramine -0.3773 [-0.9581;  0.2035]   0.00        .
112          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   2.76     0.06
114          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.08     0.13
118 BZD-intermediate    BZD-short -0.0133 [-0.3725;  0.3458]   0.69     0.26
119          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.46     0.03
122          placebo    zopiclone -0.3519 [-0.6462; -0.0576]   0.82     0.15
133        BZD-short     zaleplon  0.2856 [-0.0278;  0.5989]   0.02        .
133          placebo     zaleplon -0.1662 [-0.4351;  0.1027]   0.99        .
133        BZD-short      placebo  0.4517 [ 0.2113;  0.6922]   0.59        .
134          placebo     zaleplon -0.1662 [-0.4351;  0.1027]   0.55     0.45
137          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   1.17     0.13
140        BZD-short     zolpidem  0.0756 [-0.1777;  0.3289]   0.17        .
140          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.36        .
140        BZD-short      placebo  0.4517 [ 0.2113;  0.6922]   0.91        .
142 BZD-intermediate      placebo  0.4384 [ 0.1093;  0.7675]  12.08     0.17
144      eszopiclone      placebo  0.5293 [ 0.3606;  0.6980]   0.47     0.46
145          placebo    ramelteon -0.1293 [-0.2754;  0.0169]   0.01     0.37
153      lemborexant     zolpidem  0.5675 [ 0.4326;  0.7025]   1.14        .
153          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   0.42        .
153      lemborexant      placebo  0.9436 [ 0.8052;  1.0821]   3.32        .
154      lemborexant      placebo  0.9436 [ 0.8052;  1.0821] 110.35     0.04
158          placebo  seltorexant -0.4326 [-0.6487; -0.2166]   1.44        .
158          placebo     zolpidem -0.3761 [-0.4784; -0.2738]   2.04        .
158      seltorexant     zolpidem  0.0565 [-0.1599;  0.2729]   1.47        .
159     daridorexant      placebo  0.4688 [ 0.3718;  0.5657]   2.46     0.49
160     daridorexant      placebo  0.4688 [ 0.3718;  0.5657]   2.87     0.37

Results (random effects model):

              treat1       treat2     SMD             95%-CI
12       eszopiclone      placebo  0.5961 [ 0.1210;  1.0713]
18  BZD-intermediate      placebo  0.4530 [-0.0202;  0.9262]
47           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
51          BZD-long      placebo  0.6562 [ 0.0765;  1.2359]
51         BZD-short      placebo  0.4920 [ 0.0899;  0.8941]
51          BZD-long    BZD-short  0.1642 [-0.3957;  0.7242]
52          BZD-long    zopiclone  0.2245 [-0.5758;  1.0249]
54  BZD-intermediate     BZD-long -0.2032 [-0.8638;  0.4573]
55          BZD-long    BZD-short  0.1642 [-0.3957;  0.7242]
56  BZD-intermediate    BZD-short -0.0390 [-0.5614;  0.4834]
60           doxepin      placebo  0.3937 [-0.1866;  0.9741]
61           doxepin      placebo  0.3937 [-0.1866;  0.9741]
70         melatonin      placebo  0.0639 [-0.9218;  1.0496]
71          BZD-long    BZD-short  0.1642 [-0.3957;  0.7242]
75           placebo    ramelteon -0.1272 [-0.6896;  0.4352]
77       eszopiclone      placebo  0.5961 [ 0.1210;  1.0713]
79         BZD-short      placebo  0.4920 [ 0.0899;  0.8941]
79           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
79         BZD-short     zolpidem  0.0095 [-0.4395;  0.4584]
80           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
81           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
83  BZD-intermediate      placebo  0.4530 [-0.0202;  0.9262]
85           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
99      daridorexant     zolpidem -0.0093 [-0.4923;  0.4737]
99           placebo     zolpidem -0.4825 [-0.7389; -0.2262]
99      daridorexant      placebo  0.4732 [ 0.0346;  0.9118]
106      eszopiclone    zopiclone  0.1645 [-0.4767;  0.8056]
111 BZD-intermediate      placebo  0.4530 [-0.0202;  0.9262]
111 BZD-intermediate trimipramine  0.0686 [-0.8291;  0.9662]
111          placebo trimipramine -0.3844 [-1.2826;  0.5137]
112          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
114          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
118 BZD-intermediate    BZD-short -0.0390 [-0.5614;  0.4834]
119          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
122          placebo    zopiclone -0.4317 [-1.0900;  0.2266]
133        BZD-short     zaleplon  0.3096 [-0.3251;  0.9443]
133          placebo     zaleplon -0.1824 [-0.7590;  0.3943]
133        BZD-short      placebo  0.4920 [ 0.0899;  0.8941]
134          placebo     zaleplon -0.1824 [-0.7590;  0.3943]
137          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
140        BZD-short     zolpidem  0.0095 [-0.4395;  0.4584]
140          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
140        BZD-short      placebo  0.4920 [ 0.0899;  0.8941]
142 BZD-intermediate      placebo  0.4530 [-0.0202;  0.9262]
144      eszopiclone      placebo  0.5961 [ 0.1210;  1.0713]
145          placebo    ramelteon -0.1272 [-0.6896;  0.4352]
153      lemborexant     zolpidem  1.5063 [ 0.9183;  2.0943]
153          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
153      lemborexant      placebo  1.9888 [ 1.4178;  2.5599]
154      lemborexant      placebo  1.9888 [ 1.4178;  2.5599]
158          placebo  seltorexant -0.4878 [-1.1956;  0.2200]
158          placebo     zolpidem -0.4825 [-0.7389; -0.2262]
158      seltorexant     zolpidem  0.0053 [-0.7026;  0.7131]
159     daridorexant      placebo  0.4732 [ 0.0346;  0.9118]
160     daridorexant      placebo  0.4732 [ 0.0346;  0.9118]

Number of studies: k = 39
Number of pairwise comparisons: m = 55
Number of observations: o = 6470
Number of treatments: n = 15
Number of designs: d = 22

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI     z  p-value
BZD-intermediate 0.4384 [ 0.1093; 0.7675]  2.61   0.0090
BZD-long         0.6322 [ 0.2758; 0.9886]  3.48   0.0005
BZD-short        0.4517 [ 0.2113; 0.6922]  3.68   0.0002
daridorexant     0.4688 [ 0.3718; 0.5657]  9.48 < 0.0001
doxepin          0.3991 [ 0.1924; 0.6059]  3.78   0.0002
eszopiclone      0.5293 [ 0.3606; 0.6980]  6.15 < 0.0001
lemborexant      0.9436 [ 0.8052; 1.0821] 13.36 < 0.0001
melatonin        0.0639 [-0.5560; 0.6839]  0.20   0.8399
placebo               .                 .     .        .
ramelteon        0.1293 [-0.0169; 0.2754]  1.73   0.0830
seltorexant      0.4326 [ 0.2166; 0.6487]  3.92 < 0.0001
trimipramine     0.3773 [-0.2035; 0.9581]  1.27   0.2030
zaleplon         0.1662 [-0.1027; 0.4351]  1.21   0.2258
zolpidem         0.3761 [ 0.2738; 0.4784]  7.21 < 0.0001
zopiclone        0.3519 [ 0.0576; 0.6462]  2.34   0.0191

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                    SMD            95%-CI    z  p-value            95%-PI
BZD-intermediate 0.4530 [-0.0202; 0.9262] 1.88   0.0606 [-0.4830; 1.3890]
BZD-long         0.6562 [ 0.0765; 1.2359] 2.22   0.0265 [-0.3424; 1.6548]
BZD-short        0.4920 [ 0.0899; 0.8941] 2.40   0.0165 [-0.4074; 1.3914]
daridorexant     0.4732 [ 0.0346; 0.9118] 2.11   0.0345 [-0.4444; 1.3909]
doxepin          0.3937 [-0.1866; 0.9741] 1.33   0.1836 [-0.6053; 1.3928]
eszopiclone      0.5961 [ 0.1210; 1.0713] 2.46   0.0139 [-0.3409; 1.5332]
lemborexant      1.9888 [ 1.4178; 2.5599] 6.83 < 0.0001 [ 0.9956; 2.9820]
melatonin        0.0639 [-0.9218; 1.0496] 0.13   0.8989 [-1.2337; 1.3615]
placebo               .                 .    .        .                 .
ramelteon        0.1272 [-0.4352; 0.6896] 0.44   0.6576 [-0.8607; 1.1151]
seltorexant      0.4878 [-0.2200; 1.1956] 1.35   0.1768 [-0.5963; 1.5719]
trimipramine     0.3844 [-0.5137; 1.2826] 0.84   0.4015 [-0.8425; 1.6114]
zaleplon         0.1824 [-0.3943; 0.7590] 0.62   0.5354 [-0.8144; 1.1791]
zolpidem         0.4825 [ 0.2262; 0.7389] 3.69   0.0002 [-0.3573; 1.3223]
zopiclone        0.4317 [-0.2266; 1.0900] 1.29   0.1987 [-0.6183; 1.4816]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.1529; tau = 0.3910; I^2 = 79.8% [72.4%; 85.3%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                     Q d.f.  p-value
Total           163.71   33 < 0.0001
Within designs   30.77   18   0.0306
Between designs 132.94   15 < 0.0001
[1] "A total of 15 treatments are included in the network."
[1] "A total of 39 studies are included in this analysis."
[1] "A total of 6470 participants are included in this analysis."
[1] "The following studies were included in this analysis: 12 18 47 51 52 54 55 56 60 61 70 71 75 77 79 80 81 83 85 99 106 111 112 114 118 119 122 133 134 137 140 142 144 145 153 154 158 159 160"
[1] "Estimated heterogeneity tau-squared0.15"
[1] "Global test for inconsistency, p-value 0 (Q=133, d.o.f. 15)"
[1] "File created on 2022-06-01"
